Linked Life Data

Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.

Source:http://linkedlifedata.com/resource/pubmed/id/21646612

J. Clin. Oncol. 2011 Jul 1 29 19 2735-6; author reply 2736-8

Download in:

View as

General Info

PMID
21646612